IRWD Ironwood Pharmaceuticals Inc

Price (delayed)

$10.99

Market cap

$1.78B

P/E Ratio

12.21

Dividend/share

N/A

EPS

$0.9

Enterprise value

$1.81B

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Highlights

The quick ratio has surged by 86% year-on-year and by 47% since the previous quarter
The company's equity has surged by 76% QoQ
IRWD's revenue is down by 9% YoY but it is up by 2.3% QoQ
Ironwood Pharmaceuticals's gross profit has decreased by 4.9% YoY but it has increased by 2.9% QoQ
IRWD's debt is up by 4% year-on-year

Key stats

What are the main financial stats of IRWD
Market
Shares outstanding
161.97M
Market cap
$1.78B
Enterprise value
$1.81B
Valuations
Price to earnings (P/E)
12.21
Price to book (P/B)
16.05
Price to sales (P/S)
4.44
EV/EBIT
10.28
EV/EBITDA
10.09
EV/Sales
4.54
Earnings
Revenue
$398.43M
EBIT
$175.76M
EBITDA
$179.05M
Free cash flow
$198.52M
Per share
EPS
$0.9
Free cash flow per share
$1.23
Book value per share
$0.68
Revenue per share
$2.48
TBVPS
$3.72
Balance sheet
Total assets
$599.34M
Total liabilities
$489.15M
Debt
$467.06M
Equity
$110.19M
Working capital
$514.64M
Liquidity
Debt to equity
4.24
Current ratio
22.8
Quick ratio
23.34
Net debt/EBITDA
0.15
Margins
EBITDA margin
44.9%
Gross margin
99.8%
Net margin
35.8%
Operating margin
44%
Efficiency
Return on assets
27.3%
Return on equity
402.5%
Return on invested capital
28.6%
Return on capital employed
30.5%
Return on sales
44.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IRWD stock price

How has the Ironwood Pharmaceuticals stock price performed over time
Intraday
0%
1 week
1.48%
1 month
7.85%
1 year
2.14%
YTD
-3.51%
QTD
-1.7%

Financial performance

How have Ironwood Pharmaceuticals's revenue and profit performed over time
Revenue
$398.43M
Gross profit
$397.53M
Operating income
$175.11M
Net income
$142.76M
Gross margin
99.8%
Net margin
35.8%
IRWD's net margin has surged by 87% year-on-year and by 31% since the previous quarter
The net income has soared by 70% YoY and by 34% from the previous quarter
IRWD's operating margin is up by 29% year-on-year and by 20% since the previous quarter
The operating income has increased by 23% from the previous quarter and by 17% YoY

Growth

What is Ironwood Pharmaceuticals's growth rate over time

Valuation

What is Ironwood Pharmaceuticals stock price valuation
P/E
12.21
P/B
16.05
P/S
4.44
EV/EBIT
10.28
EV/EBITDA
10.09
EV/Sales
4.54
The EPS has surged by 67% year-on-year and by 34% since the previous quarter
IRWD's P/E is 17% below its last 4 quarters average of 14.7
The company's equity has surged by 76% QoQ
IRWD's P/S is 32% below its 5-year quarterly average of 6.5 but 6% above its last 4 quarters average of 4.2
IRWD's revenue is down by 9% YoY but it is up by 2.3% QoQ

Efficiency

How efficient is Ironwood Pharmaceuticals business performance
The return on sales has surged by 64% year-on-year and by 24% since the previous quarter
Ironwood Pharmaceuticals's ROIC has increased by 44% YoY and by 27% from the previous quarter
Ironwood Pharmaceuticals's return on assets has increased by 22% QoQ and by 18% YoY

Dividends

What is IRWD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IRWD.

Financial health

How did Ironwood Pharmaceuticals financials performed over time
The total assets is 23% more than the total liabilities
Ironwood Pharmaceuticals's current ratio has soared by 88% YoY and by 48% from the previous quarter
The quick ratio has surged by 86% year-on-year and by 47% since the previous quarter
The company's debt to equity has surged by 168% YoY but it fell by 43% QoQ
The company's equity has surged by 76% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.